| 摘要 |
The invention relates to the use of increased-molecular-weight hirudin for the manufacture of an anticoagulant for extracorporeal renal replacement therapy which does not induce an autoimmune disease and which does not cross react with autoimmune antibodies. In particular, the use according to the invention does not induce type II thrombocytopenia (HIT II), and no cross reactivity occurs with antibodies to platelet-factor-4-heparin complexes.
|
